



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

THPP-1

Cat. No.:	HY-117604		
CAS No.:	1257051-63-0		
Molecular Formula:	C ₂₃ H ₂₁ ClN ₆ O ₃		
Molecular Weight:	464.9		
Target:	Phosphodiesterase (PDE)		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 31.25 mg/mL (67.22 mM; Need ultrasonic)

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.1510 mL	10.7550 mL	21.5100 mL
	5 mM		0.4302 mL	2.1510 mL	4.3020 mL
	10 mM		0.2151 mL	1.0755 mL	2.1510 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

THPP-1, a SGC chemical probe, is a potent and orally bioavailable phosphodiesterase 10A (PDE10A) inhibitor, with K_i values of 1 nM and 1.3 nM for human and rat PDE10A, respectively. THPP-1 has excellent pharmacokinetic properties in preclinical species^[1].

IC₅₀ & Target

IC₅₀: 1-1.3 nM (PDE10A)^[1].

In Vivo

THPP-1 (0.1-1.0 mg/kg, p.o.) shows novel object recognition in rats^[1].

THPP-1 (p.o., 1-30 mg/kg) dose-dependently increases phosphorylation of GluR1 S845 in the rat striatum whereas the total levels of GluR1 in the striatum are not affected. Administration of THPP-1 also results in an associated increase in the pGluR1/GluR1 ratios at all doses examined in this study^[1].

THPP-1 (1, 3, 10 mg/kg, p.o.) significantly attenuated the stimulant effects in stimulant-induced motor activity (SIMA) in monkey^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar Hannover rats ranging from 200 to 300 g ^[1] .
Dosage:	0.1-1.0 mg/kg.
Administration:	P.O.
Result:	Showed novel object recognition.
Animal Model:	Eleven monkeys were surgically implanted with subcutaneous telemetric devices to permit the simultaneous recording of electrocorticogram (ECOG), electrooculogram (EOG), and electromyogram (EMG) activity.
Dosage:	1, 3, 10 mg/kg.
Administration:	P.O.
Result:	Significantly attenuated the stimulant effects in SIMA.
Animal Model:	Male Wistar Hannover rats ranging from 200 to 300 g ^[1] .
Dosage:	1-30 mg/kg.
Administration:	P.O. (10% Tween 80/90% water) 2 h prior to tissue collection (Pharmacokinetic Analysis).
Result:	Dose-dependently increases phosphorylation of GluR1 S845.

REFERENCES

- [1]. Smith SM, et al. The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. *Neuropharmacology*. 2013 Jan;64:215-23.
- [2]. Vardigan JD, et al. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity. *Psychopharmacology (Berl)*. 2016 Jul;233(13):2441-50.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA